Journal: Journal of Immunology Research

Article Title: Identification of Specific Cell Surface Markers on Immune Cells of Squirrel Monkeys ( Saimiri sciureus )

doi: 10.1155/2024/8215195

Figure Lengend Snippet: List of human monoclonal antibodies used for analysis.

Article Snippet: 4 , CD14 , AF700 , M5E2 , 557923 , Mouse IgG2a, k , BD Pharmingen.

Techniques:

Journal: Journal of Immunology Research

Article Title: Identification of Specific Cell Surface Markers on Immune Cells of Squirrel Monkeys ( Saimiri sciureus )

doi: 10.1155/2024/8215195

Figure Lengend Snippet: Blocking of steady state PD-1 and HLA-DR expression on mitogen stimulation of squirrel monkey PBMC (a) and IFN- γ ELISPOT (b): PBMC (1 × 10 5 ) were stimulated with Con A (2 µ g/mL) for 72 hr in the presence and absence of PD-1 (5 µ g/mL) or HLA-DR (Clone L243; 5 µ g/mL) blocking antibodies. Stimulation index was calculated by division of absorbance (A540) of PBMC (+Con A) with absorbance of PBMC (−Con A) (a). PBMC (50,000) were stimulated with Con A (2 µ g/mL) for 40 hr in the presence and absence of PD-1 (1 µ g/mL) or HLA-DR (clone L243; 5 µ g/mL) blocking antibodies for IFN- γ ELISPOT (b). In both experiments, an isotype control (IgG1 or IgG2a for PD-1 and HLA-DR, respectively) at the same concentration of PD-1 or HLA-DR was used as a control. Results from three animals are shown. Values are reported as not significant (ns), ∗ p =0.032, or ∗∗ p =0.0032.

Article Snippet: 4 , CD14 , AF700 , M5E2 , 557923 , Mouse IgG2a, k , BD Pharmingen.

Techniques: Blocking Assay, Expressing, Enzyme-linked Immunospot, Concentration Assay

Journal: Oncoimmunology

Article Title: Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

doi: 10.1080/2162402X.2017.1339855

Figure Lengend Snippet: Co-encapsulation of α-GalCer and Melan A in NP/CLEC9A augments the proliferation of Melan A-specific CD8+ T cells in vitro. A, PBMCs from HLA-A2+ donors were cultured with Melan A peptide alone (0.9 µg/ml) or supplemented with α-GalCer (10ng/ml), either free or encapsulated in NP/Clec9a or NP/IgG. Fourteen days later, the proportion of Melan A-specific (dextramer A2/Melan A26–35-specific cells, Dex/M+) CD8+ T cells were determined by flow cytometry. Data from 3 donors are shown. B, The magnitude (frequency and cell number/well) of the Melan A-specific CD8+ T cell populations from a pool of 7 healthy donors is shown. Horizontal bars indicate mean values. C, At the end of the culture, gated CD3+ expanded cells were analyzed for 6B11 labeling. The frequency of human NKT cells (CD3+ 6B11+) from healthy donors and from melanoma patients is shown at day 0 and day 14. The fold expansion of NKT cells is presented in the right panel. (D) and E, PBMCs from melanoma donors were cultured with NP/α-GalCer/Melan A/Clec9a. D, Proportions of Melan A-specific CD8+ T cells are shown at day 0 and day 14. E, The proportion of Melan A-specific CD8+ T cells (day 14) expressing IFN-γ or CD107 upon activation with T2 cells pulsed with the Melan A peptide or with an irrelevant peptide is shown. ***P < 0.001, **P < 0.01, *P < 0.05 (a Wilcoxon test (B, right panel), a Mann–Whitney U test (C, (D) and E) or a Kruskal–Wallis ANOVA (B, left panel)).

Article Snippet: V500-conjugated CD8, AF700-conjugated CD3, AF647-conjugated CCR7, FITC-conjugated CD3, V450-conjugated (CD3, CD14, CD19, CD20, CD56), FITC-conjugated IFN-γ, APC-H7-conjugated CD3, V421-conjugated HLA-DR, PECy7-conjugated CD45RA and FITC-conjugated CCR7 were all purchased from BD Biosciences.

Techniques: In Vitro, Cell Culture, Flow Cytometry, Labeling, Expressing, Activation Assay, MANN-WHITNEY